Gibson Christopher

Gibson Christopher, CEO of Recursion Pharmaceuticals (RXRX), has demonstrated a consistent pattern of selling activity over recent months, with no recorded purchases across his two reported holdings, RXRX and Pacific Biosciences (PACB). Since November 2025, Christopher has executed 12 sales of RXRX shares totaling approximately $1.3 million, with transactions ranging from $36,895 to $185,200 per filing. The most recent sale occurred on March 23, 2026, when he disposed of $130,000 worth of stock. Notably, his sales have followed a roughly monthly cadence, with additional transactions on February 19 ($138,400), February 4 ($164,800), and January 20 ($178,800). The filings also indicate derivative transactions coded as gifts (G) and option exercises (F), including a $95,154.85 transaction on February 17, 2026. Christopher’s activity is exclusively concentrated on RXRX, with no recent transactions in PACB beyond administrative filings (code A) in early March 2026. His 50 total reported trades show a complete absence of buying, with nearly $7.9 million in aggregate sell value. The steady divestment suggests an ongoing reduction in his RXRX position, though the sales appear structured rather than abrupt, with no single transaction exceeding $200,000. The lack of purchases across both holdings reinforces a clear directional bias toward liquidation rather than accumulation in his disclosed portfolio.